Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: HIV (US)

Product Code:
Publication Date:
April 2016

Can prescription barriers help other HIV brands catch up to the runaway market leader?

In the US HIV treatment market, the #1 brand has a 10% market share lead over its nearest rival. Will market barriers be the deciding factor in close races for 2nd and 3rd place?

Market Access Impact: HIV explores how cost concerns and other barriers affect market share for 8 major HIV treatments: Evotaz, Intelence, Isentress, Selzentry, Stribild, Triumeq, Truvada, and Viread.

You’ll find out which brands your brand is losing share to, which ones you’re taking it from, and why—information you can use to compete more effectively.

Not your market? Click here to see the EU report 

Request Sample Pages

Get Answers to Key Questions about HIV Drug Brands

  • Evotaz (atazanavir/cobicistat; BMS): Does Evotaz lose more market share because of pricing or formulary availability?
  • Intelence (etravirine; Janssen Biotech): Does Intelence lose more market share to Isentress or Stribild?
  • Isentress (raltegravir; Merck & Co.): Does Isentress gain more market share when competing brands are too expensive or when they’re not available on formularies?
  • Selzentry (maraviroc; ViiV Healthcare): Which market barriers cost Selzentry the most market share. How much share would it gain if they didn’t exist?
  • Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead): Do more doctors prescribe Stribild or Triumeq? Which brand has more market share?
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare): Only two FDCs saw a net share gain because of barriers. Is Triumeq one of them?
  • Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead): Is Truvada taking more market share from Stribild or is it the other way ‘round?
  • Viread (tenofovir disoproxil fumarate; Gilead): Only one monotherapy saw a net share gain because of barriers. Is it Viread?

Top Takeaways

  • Clear market leader: The most prescribed brand not only has a 12% market share advantage, it also sees twice the barrier-related share gain (net) of its nearest rival.
  • Only three brands benefit from barriers: These brands all saw a net gain in market share, while the other five saw net losses.
  • Brand awareness is high: 97% or greater among doctors surveyed for any given brand.
  • Barrier effect is uneven: The number of doctors who experience the top 3 market barriers varies greatly from brand to brand.
  • FDCs somewhat more prescribed: Although nearly all surveyed brands are widely prescribed, three of the four most prescribed brands are fixed-dose combinations. 
  • Cost barriers have the greatest impact: Barriers related to pricing and formulary availability affect more prescriptions than any others.
  • Barrier effect significant for “other” brands: Taken together, “other” brands have a greater market share than 5 of the surveyed brands, and see the third biggest net gain due to barriers. 

Exploring Market Access Issues

Market Access Impact: HIV explores key issues affecting HIV drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest effect?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge


We surveyed 100 Medical Oncologists in the US, chosen from the largest community of validated physicians in the world

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between March 2nd and 9th, 2016.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.


All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved